International conference on Cannabis and Medicinal Research November 15-16, 2018 Osaka Japan

Samantha received her Master of Science degree from the University of Guelph studying Molecular and Cellular Biology. Her experience investigating human physiology and cellular biology has allowed her to develop sophisticated laboratory and project management skills that contribute to Avicanna Inc’s (Toronto, Canada) competitive edge in the department of Research and Development. Samantha has been published on several different occasions and has lead various conferences and presentations related to plant gene manipulation, cloning and most relevant, the foundations and use benefits of medicinal cannabis.

Advancements of Cannabinoid Research and Delivery Systems

Emily Rigby completed a Bachelor of Science (Hons) at the University of the Sunshine Coast, Australia. Emily is Director of Research Programs for the Australian Institute for Medical Cannabis (AIMC), is a not-for-profit research organisation committed to open science research into medicinal cannabis, building awareness and sharing knowledge and Director of Research and Compliance for Cannatrek Medical, a fully licensed Australian medical cannabis enterprise. Emily is President of the Australian Society for Horticultural Science, Director of Protected Cropping Australia and a 2016 Nuffield Australia Scholar. Emily taught scientific research methods at the University of the Sunshine Coast for 8 years.

Medicinal Cannabis PTSD Study for Military Veterans & First Responders

Dr. Felice writes and develops educational materials, including instructional videos, for cannabis education curricula for academic institutions and private businesses such as Seattle Central College, and Medical Marijuana 411, a nationally recognized cannabis educator. His CME cannabis courses for doctors and pharmacists have now been translated into three languages. He is available for speaking and training seminars for both industry and academia. Dr. Felice continues to develop and write continuing education classes for physicians and nurses, including for the American Academy of Cannabinoid Medicine (AACM) and the Washington Association for Naturopathic Physicians (WANP) and Medical Marijuana 411. Dr. Felice is one of the few industry experts in the area of topical cannabis. Dr. Jake F. Felice is an accomplished naturopathic physician with extensive experience in cannabinoid therapeutics and medical cannabis consultations. He is licensed to practice medicine in the states of Washington and California. Dr. Felice provides ongoing education to industry in Washington State which is required by law for cannabis professionals to obtain medical consultant certifications through the Washington State Department of Health. Dr. Felice writes and develops educational materials, including instructional videos, for cannabis education curricula for academic institutions and private businesses such as Seattle Central College, and Medical Marijuana 411, a nationally recognized cannabis educator. His CME cannabis courses for doctors and pharmacists have now been translated into three languages. He is available for speaking and training seminars for both industry and academia. Dr. Felice continues to develop and write continuing education classes for physicians and nurses, including for the American Academy of Cannabinoid Medicine (AACM) and the Washington Association for Naturopathic Physicians (WANP) and Medical Marijuana 411. Dr. Felice has recently been invited to be the featured speaker at the WANP for this year’s conference focusing on clinical approaches to cannabis in the management of chronic pain. He is one of the few industry experts in the area of topical cannabis. Dr. Felice is a distinguished public speaker on medical cannabis, having participated in numerous expert panels and forums. He excels at live question and answers on this topic. His depth of education combined with his extensive public speaking skills enables Dr. Felice to explain the complexities of cannabis science to non-medical audiences. As a national cannabis brand ambassador Dr. Felice provides scientific, medical, public relations, product development, and compliance based advice for companies in emerging and existing cannabis markets. He has consulted for premier cannabis companies including Willie Nelson’s brand, Cannabis Basics, Medical Marijuana 411, Seattle Central College, and The Academy of Cannabis Science. As a consultant he has advised on the development of specialized medical cannabis products tailored to specific conditions including PTSD, chronic pain, insomnia, and traumatic brain injury (TBI). Qualified naturopathic physicians undergo rigorous training before they become licensed health-care practitioners. ND’s perform minor surgeries, such as removing cysts and suturing superficial wounds. They do not practice major surgery. Naturopathic physicians work in private practices, hospitals, clinics and community health centers. ND’s practice throughout the United States and Canada. ND’s are trained to utilize prescription drugs, although the emphasis of naturopathic medicine is the use of botanical drugs and natural healing agents. Unlike most conventional MD’s, naturopathic doctors receive in depth training on botanical drugs and their interactions with pharmaceuticals, in addition to receiving formal education on cannabis the endocannabinoid system (ECS). Dr. Felice’s clinical expertise is in the treatment of chronic pain and the improvement of human performance. He is a graduate of, and former adjunct professor of Bastyr University, the world’s leading naturopathic university. While at Bastyr, he taught Advanced Soft-Tissue Manipulation and Radiographic Lab Interpretation. Dr. Felice earned his undergraduate degree from Penn State University where he played Division I varsity lacrosse and majored in psychology with a focus on the study of peak human performance.

Medical cannabis, the endocannabinoid system, and neuroprotection

Dr. Jeremy Riggle received his Ph.D. in Analytical Chemistry from the University of Idaho in Moscow, ID, after being awarded a M.S. in Environmental Chemistry also from the University of Idaho and a B.S. in Biology from Eastern Oregon University in La Grande, OR. He then worked in the Division of Atmospheric Sciences at Desert Research Institute in Reno, NV, where he focused on the characterization and source apportionment of carbonaceous particulate matterFollowing his time at DRI, he worked in the Food Safety and Environmental Stewardship laboratory at Oregon State University in Corvallis, OR, a toxicology lab where he concentrated on the environmental fate of Polynuclear Aromatic Hydrocarbons. More recently, Dr. Riggle was an associate professor of chemistry in the Department of Chemistry & Biochemistry at his alma mater, Eastern Oregon University. Shortly after arriving at EOU, Dr. Riggle co-founded EOA, a cannabis research and quality control laboratory and, prior to joining Mary’s, spent the past several years focusing on the analytics of cannabis, its associated compounds and various cannabinoid formulations.

The potential role of cannabinoids in healing cosmetic products

Background: Attention deficit hyperactivity disorder (ADHD) may persist into adulthood and become treatment resistant to standard medication. Many patients report on a symptom relief with Cannabis. Although with noticeable symptom reduction associated, their experience is mainly restricted to THC-predominant blackmarket strains in unknown quality with the thread of prosecution. Due to the change in german legislation, Cannabis flowers can be prescribed as a narcotic medication, if guideline-therapy was ineffective or associated with intolerable side effects. Aim of the analysis was to gain a first insight into the health-related and social experiences of patients with adult ADHD, who medicate with prescribed Cannabis. Methods: Analysis of 31 questionnaires from Cannabis-patients in a specialized psychiatric practice between August 2017 and February 2018 regarding specific treatment aspects of adult ADHD. The data included pre-treatment, specific social aspects, modes of application, average daily dosages, grading of different Cannabis flowers and the use of Cannabidiol. Results: With standardized cannabinoid medication patients experienced an improvement of key symptoms and social status. Average single dose was 300 mg with a mean daily dosage of 2 grams split into 7 inhalations. A relevant amount of Cannabidiol in Cannabis Flowers led to a positive influence on impulsiveness and agitation. Acceptance of Sativex® increased with experience of a beneficial prolonged effect of oral intake and a relevant amount of CBD. Health insurances reimburse costs in 1 of 4 cases, although all patients and future prescribing doctors affirm a better quality of life. Conclusion: Cannabis can be an effective treatment alternative in adult ADHD. Cannabidiol alleviates impulsiveness and agitation. Best therapeutic results can be seen with an individualized combination of oral and inhalative cannabinoid medication.

Social and curative aspects of treatment with Cannabis in adult ADHD

Ian Quinn, Founder and CEO, Phyto Animal Health, USA

Healthy Pets; Happy Planet

Michael started his Television and film making career in the early 80’s, completing multi degrees of higher education in tv and film production. Michael having been a visual artist most of his life he had no involved or interest in politics or medicine. Life threatening illness and the awareness of how cannabis could help humanity changed Michael’s path. Michael has grass root lobbied for humanin rights, ran for state legislative office several times, and has dedicated his life’s work to a worldwide understanding and legislation of Cannabis.

Spirit, Mind, Body; What Have We Learned?

Jonathan Grunfeld completed his medical studies in Tel Aviv in 1996 and went on to specialize in adult neurology. Between 2002 and 2004 he completed a clinical fellowship in neuro-oncology in the M.D. Anderson Cancer Center in Houston, USA. Upon returning to the Asaf HaRofeh Medical Center he turned to palliative care which he has been practicing since 2005 in the Institute of oncology. In the course of this service he has accumulated experience using cannabis for the alleviation of assorted symptoms in over 4,000 patients

Obstacles to the Integration of Cannabis Based Treatments into Standard Medicine